

IPW

PATENTS

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)
Schneck and Oelke) GAU: 1614
Serial No.: 10/618,267) Examiner: tba
Filed: July 14, 2003) Docket No. 001107.00355

For: REAGENTS AND METHODS FOR ENGAGING UNIQUE CLONOTYPIC
LYMPHOCYTE RECEPTORS

THIRD SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

U.S. Patent and Trademark Office
Customer Service Window
Randolph Building
401 Dulany Street
Alexandria, VA 22314

Sir:

One PTO Form-1449 accompanies this paper and lists documents for the Examiner's consideration during this application's prosecution. We believe no fee is due; if this is incorrect, please charge our Deposit Account No. 19-0733.

Respectfully submitted,

Dated: December 14, 2005

By: Lisa M. Hemmendinger
Lisa M. Hemmendinger
Registration No. 42,653

Customer No. 22907

Substitute for form 1449A/PTO


**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1 of 1

Complete if Known

Application Number	10/618,267
Filing Date	July 14, 2003
First Named Inventor	Schneck
Group Art Unit	1614
Examiner Name	tba
Attorney Docket Number	001107.00355

**U.S. PATENT DOCUMENTS**

Examiner Initials *	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
		6,269,411	07/31/2001	REASONER	

FOREIGN PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
		WO 01/80833	11/01/2001	Salvatore Albani		
		WO 02/065992	08/29/2002	Ortho-McNeil Pharmaceutical, Inc.		
		WO 03/057171	07/17/2003	The Trustees of the University of Pennsylvania		

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		DEETHS et al., "B7-1-dependent co-stimulation results in qualitatively and quantitatively different responses by CD4 ⁺ and CD8 ⁺ T cells", <u>European Journal of Immunology</u> , Vol. 27, No. 3, 1997, pp 598-608.	
		OELKE et al., "Generation and purification of CD8 ⁺ melan-A-specific cytotoxic T lymphocytes for adoptive transfer in tumor immunotherapy", <u>Clinical Cancer Research: An Official Journal of the American Association for Cancer Research</u> , May 2000, Vol. 6, No. 5, pp 1997-2005.	
		VON BERGWELT-BAILDON et al., "Human primary and memory cytotoxic T lymphocyte responses are effectively induced by means of CD40-activated B cells as antigen-presenting cells: Potential for clinical application", <u>Blood</u> , Vol. 99, No. 9, May 1, 2002, pp 3319-3325.	
		OERTLI et al., "Artificial antigen-presenting cells engineered by recombinant vaccinia viruses expressing antigen, MHC class II, and costimulatory molecules elicit proliferation of CD4 ⁺ lymphocytes invitro", <u>Clinical and Experimental Immunology</u> , Vol. 110, No. 1, October 1997, pp 144-149.	
		NAKAMURA et al., "Dendritic cells genetically engineered to simultaneously express endogenous tumor antigen and granulocyte macrophage colony-stimulating factor elicit potent therapeutic antitumor immunity", <u>Clinical Cancer Research: An Official Journal of the American Association for Cancer Research</u> , Vol. 8, No. 8, August 2002, pp 2742-2749.	
		OELKE et al., "Ex vivo induction and expansion of antigen-specific cytotoxic T cells by HLA-Ig-coated artificial antigen-presenting cells", <u>Nature Medicine</u> , Vol. 9, No. 5, May 2003, pp 619-624.	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.